Video Programs

Panelists provide an overview of the TAILORx trial and its key findings.

Panelists provide an overview of the EUROPA trial and its key findings.

Panelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify remaining knowledge gaps, and offer final takeaways, including their thoughts on the role of luspatercept in the evolving LR-MDS treatment landscape, clinical pearls for community oncologists, and major unanswered questions that could improve outcomes for LR-MDS and anemia management in the future.

Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5.

Hope S. Rugo, MD, FASCO, discusses key takeaways from SABCS 2024 conference.

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma. Recent data from ASH 2024 highlight important patient considerations for these treatment approaches.

Experts discuss the comparative efficacy of sonrotoclax plus zanubrutinib vs venetoclax in chronic lymphocytic leukemia treatment based on updates presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024.

Panelists discuss how guideline-recommended treatment regimens for patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma should be evaluated and selected based on patient characteristics, efficacy data, and safety profiles to achieve optimal outcomes.

Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes (LR-MDS), with a focus on achieving hemoglobin levels ≥ 10, as highlighted by Santini et al in their ASH 2024 abstract, demonstrating the clinical significance of this target for improving patient outcomes.

Aimee Merino, MD, discusses how the referral process for chimeric antigen receptor T-cell therapy in early relapsed/refractory multiple myeloma involves assessing eligibility, identifying potential roadblocks, and determining which patients may not be suitable for referral based on clinical factors and treatment goals.

Panelists discuss the OlympiA trial, evaluating adjuvant olaparib post-neoadjuvant chemotherapy in patients with germline BRCA1/BRCA2 mutations and high-risk HER2-negative breast cancer, and its impact on treatment outcomes.

Panelists discuss the exploratory biomarker analysis from the KEYNOTE-522 trial, comparing perioperative pembrolizumab versus placebo plus chemotherapy in early-stage breast cancer, and its implications for treatment strategies.

Panelists discuss the INSEMA trial, comparing no axillary surgery versus axillary sentinel lymph node biopsy (SLNB) in patients with early invasive breast cancer, exploring the implications for treatment decisions and patient outcomes.

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the efficacy of this combination therapy in a patient population with newly diagnosed mHSPC. He compares its design and objectives with other established ADT plus androgen receptor pathway inhibitor (ARPI) doublet regimens such as LATITUDE, STAMPEDE D, ENZAMET, ARCHES, and TITAN, and how the study’s results, particularly its efficacy data, compare with those from other trials using abiraterone, enzalutamide, and apalutamide in the first-line setting.

James J. Harding, MD, discusses the primary (overall survival [OS]) and secondary end points (overall response rate [ORR], duration of response [DOR]) of the CheckMate 9DW trial, and explores how the inclusion of the lenvatinib (LEN) arm informs the treatment landscape, as well as the safety profiles of first-line systemic immunotherapy in patients with uHCC, focusing on the most significant adverse events seen with nivolumab plus ipilimumab (NIVO + IPI).

Evan Y. Yu, MD, discusses how the presentation of a patient with metastatic hormone-sensitive prostate cancer (mHSPC) involves evaluating key clinical features such as disease extent, symptoms, and performance status to guide treatment decisions and the selection of appropriate systemic therapies.

A panelist discusses updates from from the phase 2 study of loncastuximab + rituximab from ASH 2024.

Panelists discuss real-world evidence on dose escalation of luspatercept in lower-risk myelodysplastic syndrome (LR-MDS) (Patel et al, EHA 2024), highlighting its clinical benefits in improving patient outcomes, and share insights from the MAXILUS trial (Della Porta et al, EHA 2024), considering how this dosing strategy could influence clinical practice and enhance patient care.

A panelist discusses how molecular testing results, including ESR1 mutations, PIK3CA alterations, and other genomic findings, directly inform treatment decisions and sequencing of therapies for patients with MBC.

Hope S. Rugo, MD, FASCO, discusses how circulating tumor DNA testing enables real-time monitoring of disease progression, detection of emerging mutations, and assessment of treatment response in patients with MBC.

Panelists discuss dosing strategies for frontline luspatercept in lower-risk myelodysplastic syndrome, emphasizing individualized approaches to optimize efficacy and minimize adverse effects based on patient response and clinical factors.

Panelists discuss how intravenous immunoglobulin (IVIG) therapy may reduce infection risk in patients with multiple myeloma who are receiving teclistamab treatment.

Panelists discuss how minimal residual disease assessment demonstrates superior depth of response with ciltacabtagene autoleucel compared with standard of care in patients who have lenalidomide-refractory multiple myeloma and received 1 to 3 prior therapies.

Panelists discuss how adding a fourth drug (daratumumab) to standard triplet induction therapy may improve outcomes for patients with newly diagnosed, transplant-eligible multiple myeloma.

Panelists discuss how the AQUILA trial evaluated whether daratumumab monotherapy provides superior outcomes compared with active monitoring in high-risk smoldering multiple myeloma patients.

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier promising results by evaluating efficacy, safety, and durability of response in a larger patient population.

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with rituximab for R/R FL based on its complementary mechanism of action targeting CD19-expressing B -cells, demonstrated single-agent activity in early studies, and preliminary evidence suggesting potential synergy with anti-CD20 therapy in this setting.

Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from the AMPLIFY trial.